European Panel Revokes Symbicort Patent

Law360, New York (October 18, 2007, 12:00 AM EDT) -- An appellate panel on Thursday revoked AstraZeneca Plc's European combination patent for the asthma treatment Symbicort, well over two years after the European Patent Office upheld its validity.

The EPO's Technical Board of Appeal made its final ruling after several European generic manufacturers registered objections to the EPO's March 2005 decision on validity, AstraZeneca announced.

The company's data exclusivity, currently scheduled to expire in August 2010 in most major European markets, was unaffected by the ruling, according to AstraZeneca.

The combination patent had been set to...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.